LancsLive on MSN

Royal Blackburn Hospital A&E 'extremely busy' as urgent plea sent to patients

Health bosses have issued an urgent plea to patients while issuing a warning about Royal Blackburn Hospital's A&E department.

Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results

Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product salesReceived 152 new patient start forms for EMPAVELI® ...
RMD Open

AI-based HRCT quantification reveals DLCO and TLC as key determinants of ILD severity in connective tissue diseases

Objective Interstitial lung disease (ILD) represents the most common and severe organ manifestation observed in patients ...

DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung …

Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic NSCLC ...
Le Lézard

Currax Pharmaceuticals to Spotlight New Research at ObesityWeek® 2025 Highlighting Craving Control, Behavioral Adherence, and Subpopulation Outcomes with CONTRAVE®

Currax Pharmaceuticals LLC ("Currax"), a pharmaceutical, company that delivers life-changing medicines to patients with chronic, progressive diseases, is set to present data at ObesityWeek® 2025, the ...
Le Lézard

Johnson & Johnson announces first head-to-head study comparing IMAAVYtm with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting

Johnson & Johnson today announced plans to initiate the first head-to-head study comparing FcRn blockers for patients with generalized myasthenia gravis (gMG), which aims to affirm IMAAVYtm ...